9 citations
,
April 2018 in “Journal of Dermatological Treatment” This study found that oral tofacitinib monotherapy improved nail changes in 73.3% of adults with moderate-to-severe alopecia areata over a median period of 5 months, but nail improvement was not linked to the severity of hair loss or hair regrowth.
May 2015 in “Cancer research” This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.
August 2018 in “Journal of the American Academy of Dermatology” This review discusses the evidence for biotin supplementation in treating hair loss, concluding that its benefits are poorly supported by data and advising against routine use without more compelling future trials.
April 2026 in “International Journal of Molecular Sciences” This review synthesizes recent research on how Wnt signaling regulates skin, hair follicle, and nail regeneration, highlighting its compartment-specific roles and discussing targeted strategies for treating conditions like alopecia, chronic wounds, and skin cancer.
7 citations
,
December 2016 in “British Journal of Dermatology” This report presents evidence that alopecia areata incognita may be a possible mechanism of hair loss in patients with Cronkhite–Canada syndrome.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.
40 citations
,
June 2021 in “Clinical, cosmetic and investigational dermatology” This review explores the efficacy and outcomes of using JAK inhibitors for treating alopecia areata, noting advancements in understanding the disease's pathomechanisms and suggesting that JAK inhibitors may offer targeted therapeutic benefits by blocking specific inflammatory pathways involved in this chronic condition.
27 citations
,
December 2015 in “Clinical and Experimental Dermatology” This study found that hair regrowth occurred in 72.2% of alopecia areata patients treated with diphencyprone, with disease extent at baseline and duration affecting outcomes.
13 citations
,
November 2012 in “Journal of The European Academy of Dermatology and Venereology” This study found that topical clobetasol propionate cream provided a modest improvement in hair regrowth for alopecia areata patients, though those with atopy had higher relapse rates after treatment completion.
4 citations
,
January 2022 in “Drug design, development and therapy” This study demonstrated that intramuscular corticosteroids were effective for severe alopecia areata, with significant hair regrowth in 80.2% of patients, though a high relapse rate was noted post-treatment. Nail involvement and disease duration over six months negatively impacted outcomes.
2 citations
,
February 2014 in “Hair therapy & transplantation” This article reviews the autoimmune mechanism and potential environmental triggers of alopecia areata, focusing on cytokines, but does not provide new research findings.
2 citations
,
January 1996 in “Annals of saudi medicine/Annals of Saudi medicine” This study found that severe forms of alopecia areata may be associated with poor treatment response, particularly in cases with extensive hair loss, juvenile onset, or nail changes.
1 citations
,
December 2023 in “Experimental Dermatology” This study reported that 57.4% of children under 10 with early-onset alopecia areata experienced over 50% hair regrowth after treatment with topical corticosteroids, noting that those under 4 showed significantly better responses, although personal atopic history was the only differing prognostic factor.
1 citations
,
June 2015 in “Australasian Journal of Dermatology” This case report describes a patient with Cronkhite–Canada syndrome, where immunosuppression and nutritional support led to disease remission.
June 2023 in “British Journal of Dermatology” This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.
May 2023 in “Clinical and Experimental Dermatology” Alopecia areata has a high chance of persisting and relapsing, with a significant risk of total hair loss, especially if it starts in childhood.
109 citations
,
May 2011 in “Dermatologic Therapy” This article reviews the characteristics, associations, and diagnostic criteria for alopecia areata and reports no new clinical findings; the authors note the disease's unpredictable course and variable prognosis.
July 2018 in “British Journal of Dermatology” Hair regrowth was seen in 83% of children with alopecia, immune system plays a role in the condition, and various treatments showed effectiveness for hair and nail disorders.
26 citations
,
October 2016 in “Case Reports in Dermatology” In this study, tofacitinib treatment in a male patient with alopecia areata led to significant hair regrowth and improvement in nail dystrophy symptoms, restoring finger function within 10 months.
1 citations
,
July 2019 in “British Journal of Dermatology” This study found that 15% minoxidil topical solution was more effective than low-level laser therapy in improving hair regrowth and patient satisfaction in individuals with androgenetic alopecia.
February 2026 in “Clinical Drug Investigation” In this study, patients with severe alopecia areata who were treated with baricitinib 4 mg/day for 48 weeks showed significant improvements in both hair regrowth and nail abnormalities, although the correlation between hair and nail improvement was weak.
May 2009 in “Medical and surgical dermatology/Medical & surgical dermatology” Hair and nail conditions can stabilize or improve over time, and new treatments show promise.
October 2023 in “Dermatology practical & conceptual” This study found that pulse corticosteroids effectively induce hair regrowth in alopecia areata, with betamethasone showing higher efficacy but more side effects, and treatment success varying depending on age, onset time, and disease type.
March 2024 in “International Journal of Dermatology” In this case report, a 40-year-old male with alopecia universalis and twenty-nail dystrophy showed significant nail improvement and partial hair regrowth after six months of baricitinib treatment, improving his quality of life.
January 2005 in “Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München)” This study found that a significant portion of alopecia areata patients achieved at least partial hair regrowth with diphenylcyclopropenon therapy, which was more effective in certain subtypes and disease durations.
275 citations
,
November 2002 in “International Journal of Dermatology” This study found that among an Asian population with alopecia areata, commonly first episodes occurred before age 40, with severe cases linked to psychological effects and treatments showing significant regrowth.
39 citations
,
March 1976 in “British Journal of Dermatology” This article reviews the use of intralesional steroid therapy in dermatology, highlighting its application in conditions like nail disorders and cystic acne, but it reports no new clinical results.
4 citations
,
December 2001 in “Endoscopy” In this case study, administration of prednisolone and Bactrim for a woman with Cronkhite-Canada syndrome led to the cessation of diarrhea, increased serum protein, and improvement in hyperpigmentation and hair regrowth.
February 2021 in “International journal of research in dermatology” This study reports an 8-year-old boy with trachyonychia, lichen planus, and alopecia areata who showed significant improvement in hair growth, nail condition, and skin lesions after 6 months of biweekly pulse systemic corticosteroid therapy.
In this study, intralesional steroids were the most effective treatment for alopecia areata, achieving cosmetically acceptable hair regrowth in 88% of patients, compared to cryotherapy at 76%, phenol at 52%, and phototherapy at 36%.